Moffitt Cancer Center’s Phase 3 Study May Be Game-Changer for Acute Myeloid Leukemia

Moffitt Cancer Center’s Phase 3 Study May Be Game-Changer for Acute Myeloid Leukemia

Moffitt Cancer Center’s Phase 3 Study May Be Game-Changer for Acute Myeloid Leukemia

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

“Acute myeloid leukemia is an aggressive blood cancer with very low rates of treatment success, especially in older patients,” explained Jeffrey Lancet, M.D., senior member of the Department of Malignant Hematology and chief of the Leukemia Section at Moffitt.

Related posts

UNF physics lecturer receives U.S. Patent

Nirmalkumar Patel, a University of North Florida physics associate lecturer, received a U.S. Patent for…

UNF professor reports on returning to exercise post-pandemic, staying healthy in the new year

Dr. James Churilla, UNF professor and Exercise Science and Chronic Disease Graduate Program director, recently…

FIT Biochemist Studies Farming on Mars

Farming on Mars will be a lot harder than ‘The Martian’ made it seem.  Growing…